Drug intelligence / Profile preview

rHCT3-2

Development stage: Preclinical
Lead developer: Theialife

Overview

rHCT3-2 is a drug candidate developed by Theialife, described as part of an innovative molecular platform aimed at addressing various ophthalmological unmet needs. Specifically, this molecular platform is uniquely positioned to address Keratoconus and Corneal blindness. Theialife is a clinical-stage virtual biopharmaceutical company focused on novel drug discovery and development for ophthalmology applications.

Targets

MMP12 (Macrophage Metalloelastase)COL1A2 (Type I collagen alpha-2 chain)

Beyond the preview

Go deeper on rHCT3-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rHCT3-2.

Explore the full profile